144 related articles for article (PubMed ID: 34019301)
1. Cell-Based Methods for the Identification of Myc-Inhibitory Small Molecules.
Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA
Methods Mol Biol; 2021; 2318():337-346. PubMed ID: 34019301
[TBL] [Abstract][Full Text] [Related]
2. Cell-based methods for the identification of MYC-inhibitory small molecules.
Burkhart CA; Haber M; Norris MD; Gudkov AV; Nikiforov MA
Methods Mol Biol; 2013; 1012():255-64. PubMed ID: 24006071
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.
Felsenstein KM; Saunders LB; Simmons JK; Leon E; Calabrese DR; Zhang S; Michalowski A; Gareiss P; Mock BA; Schneekloth JS
ACS Chem Biol; 2016 Jan; 11(1):139-48. PubMed ID: 26462961
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Jeong KC; Ahn KO; Yang CH
Mol Biosyst; 2010 Aug; 6(8):1503-9. PubMed ID: 20485733
[TBL] [Abstract][Full Text] [Related]
6. A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.
Tadele DS; Robertson J; Crispin R; Herrera MC; Chlubnová M; Piechaczyk L; Ayuda-Durán P; Singh SK; Gedde-Dahl T; Fløisand Y; Skavland J; Wesche J; Gjertsen BT; Enserink JM
J Biol Chem; 2021; 296():100179. PubMed ID: 33303632
[TBL] [Abstract][Full Text] [Related]
7. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
8. Tracing MYC Expression for Small Molecule Discovery.
Steinberger J; Robert F; Hallé M; Williams DE; Cencic R; Sawhney N; Pelletier D; Williams P; Igarashi Y; Porco JA; Rodriguez AD; Kopp B; Bachmann B; Andersen RJ; Pelletier J
Cell Chem Biol; 2019 May; 26(5):699-710.e6. PubMed ID: 30880156
[TBL] [Abstract][Full Text] [Related]
9. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
10. Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce
Medina JR; Tian X; Li WH; Suarez D; Mack JF; LaFrance L; Martyr C; Brackley J; Di Marco C; Rivero R; Heerding DA; McHugh C; Minthorn E; Bhaskar A; Rubin J; Butticello M; Carpenter C; Nartey EN; Berrodin TJ; Kallal LA; Mangatt B
J Med Chem; 2021 Nov; 64(21):16056-16087. PubMed ID: 34669409
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening and Triage Assays Identify Small Molecules Targeting c-MYC in Cancer Cells.
Kallal LA; Waszkiewicz A; Jaworski JP; Della Pietra A; Berrodin T; Brady P; Jurewicz AJ; Zeng X; Payne L; Medina JR; Doepner-Buser C; Mangatt B
SLAS Discov; 2021 Feb; 26(2):216-229. PubMed ID: 33482073
[TBL] [Abstract][Full Text] [Related]
12. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
13. MYC Analysis in Cancer and Evolution.
Hartl M; Bister K
Methods Mol Biol; 2021; 2318():87-117. PubMed ID: 34019288
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression.
Frenzel A; Zirath H; Vita M; Albihn A; Henriksson MA
PLoS One; 2011; 6(11):e27988. PubMed ID: 22132187
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
16. A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide.
Fan-Minogue H; Bodapati S; Solow-Cordero D; Fan A; Paulmurugan R; Massoud TF; Felsher DW; Gambhir SS
Mol Cancer Ther; 2013 Sep; 12(9):1896-905. PubMed ID: 23825064
[TBL] [Abstract][Full Text] [Related]
17. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
18. Targeting MYC: From understanding its biology to drug discovery.
Ross J; Miron CE; Plescia J; Laplante P; McBride K; Moitessier N; Möröy T
Eur J Med Chem; 2021 Mar; 213():113137. PubMed ID: 33460833
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced inhibition of Myc activity in monocytic cells.
Larsson LG; Bahram F; Wu S; Oberg F; Nilsson K; Lüscher B
Curr Top Microbiol Immunol; 1997; 224():191-200. PubMed ID: 9308242
[No Abstract] [Full Text] [Related]
20. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
Ahmadi SE; Rahimi S; Zarandi B; Chegeni R; Safa M
J Hematol Oncol; 2021 Aug; 14(1):121. PubMed ID: 34372899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
